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A B S T R A C T
Lung cancer survivors are at risk for physical ﬁtness and autonomic function impairments. In a cross-sectional
study of consecutive lung cancer survivors post-curative intent therapy, we assessed and identiﬁed predictors of
resting heart rate variability (HRV) and heart rate recovery (HRR), deﬁned as standard deviation of normal-to-
normal-R-to-R intervals (SDNN) and root-mean-square-of-successive-diﬀerences (rMSSD) from routine out-
patient single 10-s electrocardiographs (ECGs) and diﬀerence in heart rate (HR) at 1-minute following and the
end of the six-minute-walk-test (6MWT), respectively. In 69 participants, the mean (SD) HRR was -10.6 (6.7)
beats. Signiﬁcant independent predictors of HRR were age and HR change associated with the 6MWT. In a subset
of 41 participants with available ECGs, the mean (SD) SDNN and rMSSD were 19.1 (15.6) and rMSSD 18.2 (14.6)
ms, respectively. Signiﬁcant independent predictors of HRV were supine HR, HRR, and total lung capacity. HRV/
HRR may be useful physiological measures in studies aimed at improving physical ﬁtness and/or autonomic
function in lung cancer survivors.
1. Introduction
Lung cancer is the second-most commonly diagnosed cancer in the
United States (US) (Siegel et al., 2018). The number of lung cancer
survivors is increasing partly due to advances in therapy and possibly
screening (Vachani et al., 2017). Lung cancer survivors suﬀer from the
negative health consequences associated with aging, health behaviors,
comorbidities, and/or lung cancer and its treatment (Pozo et al., 2014).
Physiological evaluation in lung cancer is most commonly performed in
the preoperative context to measure or estimate peak oxygen con-
sumption – the gold-standard measure of cardiorespiratory ﬁtness –
which is an independent predictor of perioperative morbidity and
mortality in patients being considered for major lung resection (Brunelli
et al., 2013). More recently, the utility of physiological evaluation
outside of the preoperative context has been described, including in
post-treatment lung cancer survivors to identify health impairments
(Ha et al., 2016).
Heart rate variability (HRV) and heart rate recovery (HRR) are in-
terrelated measures of physical ﬁtness and/or autonomic function
(Kiviniemi et al., 2017) which plays important physiological roles in the
homeostasis of important organs, including heart and lungs (Ha, Fuster
et al., 2015). HRV is decreased in heavy smokers (Cagirci et al., 2009)
and increases with reduction in cigarette smoking (Munjal et al., 2009).
Impaired HRR has been reported in patients with chronic obstructive
pulmonary disease (COPD), diabetes, and heart failure (Curtis and
O’Keefe, 2002), the three-most common comorbidities in lung cancer
(Islam et al., 2015). Moreover, antineoplastic therapy can also lead to
neuropathy and autonomic dysfunction (Starobova and Vetter, 2017),
further modulating heart rate measures. Critically, impaired HRR is
associated with worse survival in patients undergoing exercise testing,
independent of standard cardiac risk factors and workload achieved
(Cole et al., 1999). Therefore, HRV and HRR may be additional domains
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of physiological evaluation that have diagnostic, predictive, and prog-
nostic utility in lung cancer survivors.
Traditionally, HRV is obtained from electrocardiographs (ECGs) of
at least 240 s in duration (ESC, 1996) and HRR from maximal exercise
testing (Adabag and Pierpont, 2013). In recent years, HRV obtained
from routine, outpatient, 10-s ECGs is reported as more readily-avail-
able and has reference values available for interpretation (O’Neal et al.,
2016). HRV obtained from 10-s ECGs, in single and repeated measures,
has been validated (Munoz et al., 2015) and shown to be prognostic
independent of cardiac risk factors (de Bruyne et al., 1999) and in in-
dividuals without cardiovascular disease (O’Neal et al., 2016). Also,
HRR from submaximal (Cole et al., 2000) and functional exercise
testing is associated with clinical outcomes in various patient popula-
tions including lung cancer (Ha et al., 2015).
The identiﬁcation of predictors of HRV and HRR may provide im-
portant insights into factors that could be modiﬁed to improve lung
cancer survivorship. In this study, we aimed to identify predictors of
HRV and HRR in lung cancer survivors eligible for long-term cure. We
hypothesized that resting HRV measured from a single, routine, out-
patient 10-s ECG and HRR following functional exercise testing are
inter-dependently associated and can be used to assess physical ﬁtness
and/or autonomic function in this patient population.
2. Methods
2.1. Study overview
We previously performed a cross-sectional study, in which we en-
rolled 87% of eligible lung cancer survivor following curative-intent
treatment, to assess and analyze the relationship between functional
exercise capacity and cancer-speciﬁc quality of life (QoL) (Ha et al.,
2018). In the present study, we enrolled additional participants to
identify predictors of HRV and HRR and explore their inter-depen-
dence. In brief, we identiﬁed eligible patients from a tumor board list of
consecutive lung cancer cases managed at the VA San Diego Healthcare
System (VASDHS). Between July 2016 and March 2018, we mailed
information letters to eligible patients diagnosed with/managed for
lung cancer at the VASDHS since October 2010 and followed up with a
telephone call approximately one week later to gauge their interest. We
obtained written informed consent from all enrolled participants and
followed standard recommendations to report our ﬁndings (von Elm
et al., 2007). The VASDHS Institutional Review Board approved our
protocol (no. H150158).
2.2. Participants
We included lung cancer survivors who completed curative-intent
lung cancer treatment, deﬁned as lung cancer resection surgery, deﬁ-
nitive radiation, or concurrent chemoradiation for stage I-IIIA disease
≥1 month previously. We excluded patients who were unable to per-
form functional exercise testing, due to dementia (n= 2), bilateral
below-knee amputation (n= 2), or quadriplegia (n=1). For HRV
measures, we additionally excluded patients with atrial arrhythmias,
atrial or ventricular pacing, or frequent premature atrial or ventricular
contractions (PAC/PVCs).
2.3. Heart rate variability
We used routine, outpatient, 12-lead, 10-ECGs obtained for clinical
indications and within six months of study enrollment to assess HRV.
We deﬁned HRV as the standard deviation of normal-to-normal R-R
intervals (SDNN) and root-mean-square of successive diﬀerences
(rMSSD) from these 10-s ECGs, previously shown to correlate and agree
well with the gold-standard 240-300-s tracings (Pearson’s r 0.85-0.86,
Bland-Altman limits of agreement 0.08-0.10, and Cohen’s d 0.15-0.17
for rMSSD) (Munoz et al., 2015). We visually inspected all ECGs and
excluded those with atrial arrhythmias or atrial or ventricular pacing,
or contained>50% beats that were PAC/PVCs (O’Neal et al., 2016). In
any included ECG that had PAC/PVCs, we additionally excluded the
beats before and after them from HRV measurements, as suggested by
previous literature (O’Neal et al., 2016). We measured normal-to-
normal R-R intervals manually using electronic calipers in the GE®
MUSE editor software.
2.4. Heart rate recovery
We obtained HRR following the six-minute walk test (6MWT) as
supported by existing literature (Minai et al., 2012; Ha et al., 2015). We
performed the 6MWT according to the standard protocol at the
VASDHS which follows the American Thoracic Society (ATS) Pul-
monary Function Standards Committee recommendations (ATS
Committee on Proﬁciency Standards for Clinical Pulmonary Function
Laboratories, 2002), modiﬁed to include HRR evaluation. In brief, we
obtained pre-6MWT vital signs with the patient in the upright, seated
position. We then instructed participants to walk as far as possible for
six minutes in a 130-ft (40-m) hallway. At the end of six minutes, we
instructed participants to sit down for post-6MWT measures. We used a
ﬁnger-probe pulse oximeter to obtain heart rate (HR) and oxygen (O2)
saturation levels, and deﬁned HRR as the diﬀerence, in beats, in HR at
1-minute following completion of the 6MWT and at the end of the
6MWT. Participants who had supplemental O2 prescribed used their
own equipment at the same ﬂow rate as their regular prescription. We
did not conduct practice tests or ECG monitoring as per ATS re-
commendations (ATS Committee on Proﬁciency Standards for Clinical
Pulmonary Function Laboratories, 2002). All HRV and HRR measure-
ments were obtained by one observer (DH) blinded to all baseline
characteristics and HRR or HRV measurements.
2.5. Covariates
We collected a thorough list of clinical characteristics related to
physical ﬁtness and/or autonomic function that included age, sex,
ethnicity, smoking history, comorbidities (e.g. chronic cardiovascular
and pulmonary diseases), medications (e.g. beta-blockers, inhibitors of
the renin-angiotensin system), lung function [forced expiratory volume
in 1 s (FEV1), total lung capacity (TLC), diﬀusion capacity of the lung
for carbon monoxide (DLCO)], and echocardiographic ﬁndings where
available. Lung cancer characteristics included histologic subtype,
stage, and treatment.
2.6. Statistical analyses
We summarized descriptive statistics as means and standard de-
viations (SDs) for all continuous variables and as counts and percen-
tages for categorical variables. We used independent-sample t-tests and
chi-square tests to compare diﬀerences in clinical characteristics be-
tween participants included for HRV and HRR measurements. Both
HRV and HRR were recorded and analyzed as continuous variables. We
interpreted SDNN and rMSSD using reference values for stage I-II non-
small cell lung cancer (NSCLC) patients (De Couck and Gidron, 2013),
the six-minute walk distance (6MWD) using reference equations in
healthy adults (Enright and Sherrill, 1998), and HRR using a cutoﬀ of
≤ 12-beat decrease to indicate impairment (Cole et al., 1999; Ha et al.,
2015). We also used reference values provided in the literature to
compare HRV measures between our cohort and historical controls.
We transformed SDNN and rMSSD into normal distribution using
natural logarithms as supported by previous literature (De Couck and
Gidron, 2013). We used correlation coeﬃcients, and univariable (UVA)
and multivariable (MVA) linear regressions to assess and analyze the
relationship between baseline characteristics and HRV and HRR. For
MVAs, we used stepwise, backward selection modeling starting with all
baseline characteristics with p < 0.20 in UVAs. To identify predictors
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of HRV, we performed MVAs with and without supine HR from routine
outpatient ECGs, as HR has been shown to have both physiological and
mathematical relationships with HRV measures (Sacha, 2014). We used
regression coeﬃcients (β), 95% conﬁdence intervals (CIs), and coeﬃ-
cients of determination (R2 and partial R2) for interpretation, and de-
ﬁned statistical signiﬁcance as p < 0.05 in two-tailed tests. IBM®
SPSS® Statistics software versions 23.0 and 24.0 were used for analyses.
3. Results
3.1. Participants
We enrolled 69 lung cancer survivors following curative intent
treatment to undergo 6MWT and HRR evaluation. Of these participants,
a subset of 41 participants had routine outpatient ECGs obtained
clinically within 6 months of enrollment and met inclusion criteria for
HRV measurements (Fig. 1). The baseline clinical characteristics for
both cohorts are described in Table 1; most participants were white
males who were current or former smokers and underwent either lung
cancer resection surgery or deﬁnitive radiation for treatment. There
were no signiﬁcant diﬀerences in clinical characteristics between co-
horts except for those in the HRV cohort having a higher percentage of
early stage (I-II) lung cancer and receipt of surgical treatment (Table 1).
3.2. Assessments and identifying predictors of HRV (N=41)
The mean (SD) SDNN and rMSSD were 19.1 (15.6) and 18.2 (14.6)
ms, respectively, and their natural logarithm transformed values 2.72
(0.64) and 2.69 (0.63). Twenty-four participants (59%) had impaired
SDNN and rMSSD, deﬁned as < the mean reference values derived
from single 10-s ECGs for stage I-II NSCLC patients (E-Table 1) (De
Couck and Gidron, 2013). There was no signiﬁcant diﬀerence in SDNN
(p=0.33) or rMSSD (p= 0.27) between our cohort and historical stage
I-II NSCLC patients (De Couck and Gidron, 2013). Compared to in-
dividuals without cardiovascular disease included in the Multi-Ethnic
Study of Atherosclerosis (O’Neal et al., 2016), lung cancer survivors
included in our cohort had a mean diﬀerence of -5.04 ms (95% CI -9.96,
-0.12, p= 0.045) in SDNN and -9.08 ms (95% CI -13.7, -4.47,
p < 0.001) in rMSSD.
In UVA (E-Table 2), clinical characteristics signiﬁcantly/borderline
associated with HRV were age, TLC % predicted, supine HR, pre-6MWT
HR, HR change associated with the 6MWT, and HRR following the
6MWT (Table 2). Exploratory UVA in 27 participants with ECGs ob-
tained post-lung cancer treatment showed no signiﬁcant association
between primary treatment modality and HRV (p=0.36 for Ln-SDNN,
and p= 0.37 for Ln-rMSSD). In MVAs including all clinical character-
istics with p < 0.20 in UVAs, in a model that also contained age, TLC
Fig. 1. Flow Diagram of Included Participants.
Shaded boxes indicate cohorts analyzed.
6MWT=six-minute walk test; ECG=electrocardiogram; HRR=heart rate re-
covery; HRV=heart rate variability; PAC=premature atrial contraction;
PVC=premature ventricular contraction.
Table 1
Participant Characteristics.
Participant Characteristic
(VASDHS, 2016-2018)
HRR
Cohort(N=69)
HRV
Subset(N=41)
P-value‡
Age, year, mean (SD) 71.0 (8.4) 69.7 (8.4) 0.43
White race, n (%) 63 (91) 35 (85) 0.75
Male sex, n (%) 66 (96) 39 (95) 0.90
BMI, kg/m2, mean (SD) 26.5 (4.8) 26.5 (5.1) 1.00
Smoking history, n (%) 0.92
Current 22 (32) 14 (34)
Former 41 (59) 23 (56)
Never 6 (9) 4(10)
Pack years, mean (SD) 52.8 (32.2) 53.2 (36.4) 0.95
Comorbidities, n (%)
Hypertension 57 (83) 31 (76) 0.38
Hyperlipidemia 57 (83) 33 (81) 0.78
Diabetes 18 (26) 11 (27) 0.93
Atrial arrhythmia* 17 (25) Excluded N/A
CAD 25 (36) 18 (44) 0.43
HF† 17 (25) 9 (22) 0.75
COPD/asthma 51 (74) 30 (73) 0.93
OSA 16 (23) 12 (29) 0.48
Anxiety/Depression/
PTSD
21 (30) 11 (27) 0.69
Other cancers 29 (42) 16 (39) 0.76
Medications, n (%)
Beta-blockers 31 (45) 19 (46) 0.89
ACE-I/ARB 27 (39) 16 (39) 0.76
Pulmonary function, mean
(SD)
FEV1/FVC, % 59.9 (14.9) 61.8 (13.8) 0.51
FEV1, % predicted 71.1 (25.2) 71.6 (23.7) 0.92
TLC, % predicted** 110.9 (22.3) 108.1 (22.8) 0.53
DLCO, % predicted 78.6 (25.6) 79.8 (23.8) 0.81
Lung cancer characteristics
Clinical stage, n (%) <0.01
I 55 (80) 30 (73)
II 4 (6) 10 (24)
IIIA 10 (15) 1 (2)
Histologic subtype, n (%) 0.62
Adenocarcinoma 33 (48) 23 (56)
Squamous cell
carcinoma
17 (25) 9 (22)
Presumed 14 (20) 6 (15)
Primary treatment, n (%) <0.001
Surgical resection 34 (49) 31 (76)
Deﬁnitive radiation 25 (36) 2 (5)
Chemoradiation 10 (15) 8 (20)
Bolded variables indicate statistically-signiﬁcant diﬀerences between cohorts.
ACE-I= angiotensin converting enzyme inhibitor; ARB=angiotensin II re-
ceptor blocker; BMI= body-mass index; CAD= coronary artery disease;
COPD= chronic obstructive pulmonary disease; DLCO = diﬀusion capacity of
the lung for carbon monoxide; FEV1 = forced expiratory volume in 1 s;
FVC= forced vital capacity; HF=heart failure; OSA=obstructive sleep
apnea; PTSD=posttraumatic stress disorder; SD= standard deviation; TLC=
total lung capacity.
* Deﬁned as any history of, including paroxysmal atrial ﬁbrillation or ﬂutter,
treated with medical therapy or ablation.
** Data available in 34 and 58 participants for HRV and HRR cohorts, respec-
tively.
† Deﬁned as ejection fraction<50% or clinical documentation of systolic heart
failure.
‡ Independent sample t-tests for continuous variables and chi-square likelihood
ratio tests for categorical variables.
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% predicted, and pre-6MWT HR, and HR change associated with the
6MWT, supine HRR was a consistent signiﬁcant independent predictor
of HRV (Table 3A, Fig. 2 Ai-ii & E-Figure 1A). When supine HR was not
included, MVAs showed that total lung capacity and HRR were sig-
niﬁcant independent predictors of HRV (Table 3B, Fig. 2 Aiii-iv & E-
Fig. 1B-C).
3.3. Assessments and identifying predictors of HRR (N=69)
The mean (SD) 6MWD was 342 (123) m, 66 (24) % predicted, with
40 participants (58%) having impaired functional exercise capacity as
deﬁned by standard equations for normal healthy adults (Enright and
Sherrill, 1998). Following the 6MWT, the mean (SD) HRR was -10.6
(6.7) beats; 45 participants (65%) had impaired HRR as deﬁned by a
cutoﬀ of ≤12-beat decrease (E-Table 1) (Cole et al., 1999; Ha et al.,
2015).
In UVA (E-Table 3), hyperlipidemia, atrial arrhythmia, pre-6MWT
HR, HR change associated with the 6MWT, and 6MWD were associated
with HRR (Table 2); lung cancer histologic subtype, stage, and primary
treatment modality (surgical resection, deﬁnitive radiation, or che-
moradiation) were not associated with HRR (E-Table 3). In MVAs and a
ﬁnal model (Table 4) that also included hyperlipidemia and pre-6MWT,
age and HR change associated with the 6MWT were signiﬁcant in-
dependent predictors of HRR (Fig. 2B). When patients with a history of
paroxysmal, persistent, or permanent atrial arrhythmia managed with
medical and/or ablation therapy were excluded (UVA results are shown
in E-Table 3), similar results were obtained; heart failure with reduced
ejection fraction was additionally found to be a signiﬁcant predictor of
HRR (Table 4).
3.4. HRR-HRV inter-dependence
Heart rate recovery following the 6MWT correlated moderately-well
with HRV (Spearman’s ρ -0.38, p= 0.01 for SDNN and -0.41, p= 0.008
for rMSSD, respectively). Impaired SDNN/rMSSD was concordant with
HRR in 69% of cases. Overall, the mean HRR for participants with
Table 2
UVA – Statistically Signiﬁcant or Borderline-Signiﬁcant Predictors of HRV and HRR.
HRV (Ln-SDNN) (N=41) HRV (Ln-rMSSD) (N=41) HRR (N=69)
Clinical Characteristic β R2 P-value β R2 P-value β R2 P-value
Age, per year 0.03 0.11 0.04 0.02 0.09 0.052 NS/BS NS/BS NS/BS
Hyperlipidemia (N/Y) NS/BS NS/BS NS/BS NS/BS NS/BS NS/BS −4.95 0.08 0.02
Atrial arrhythmia (N/Y) N/A* N/A* N/A* N/A* N/A* N/A* 3.68 0.06 0.048
TLC, % predicted 0.01 0.11 0.053 0.01 0.11 0.06 NS/BS NS/BS NS/BS
Supine† HR, beats/min −0.02 0.23 0.001 −0.02 0.24 0.001 0.19 0.21 0.003
Pre-6MWT HR, beats/min −0.01 0.08 0.08 −0.01 0.08 0.08 0.16 0.11 0.01
HR change, beats 0.02 0.11 0.04 0.02 0.12 0.03 −0.40 0.45 <0.001
SBP change, mmHg NS/BS NS/BS NS/BS NS/BS NS/BS NS/BS −0.08 0.04 0.09
6MWD, m NS/BS NS/BS NS/BS NS/BS NS/BS NS/BS −0.02 0.10 0.01
HRR, beat −0.04 0.15 0.01 −0.04 0.16 0.01 N/A N/A N/A
NS/BS= not signiﬁcant or borderline signiﬁcant (p≥ 0.10).
Bolded values indicate statistically signiﬁcant association at p < 0.05.
6MWD= six-minute walk distance; 6MWT= six-minute walk test; ECG=electrocardiograph; HR=heart rate; HRR=heart rate recovery; HRV=heart rate
variability; Ln= natural logarithm; SBP= systolic blood pressure; SDNN= standard deviation of normal-to-normal R-R intervals; rMSSD= root mean square of
successive diﬀerences; TLC= total lung capacity; UVA=univariable linear regression analysis.
* Excluded per inclusion/exclusion criteria.
† Obtained on routine outpatient ECGs.
Table 3
MVA*–Independent Predictors of HRV (N=41).
(A) With Supine HR
Ln-SDNNa Ln-rMSSDb
Variable β (95% CI) Partial R2 P-value β (95% CI) Partial R2 P-value
Age, year 0.02 (-0.01, 0.04) 0.09 0.11 0.02 (-0.01, 0.04 0.06 0.18
TLC, % predicted 0.01 (0.00, 0.02) 0.10 0.10 0.01 (0.00, 0.03) 0.10 0.09
Pre-6MWT HR, beats/min 0.01 (0.00, 0.03) 0.09 0.12 0.01 (0.00, 0.03) 0.08 0.13
HR change, beats 0.02 (0.00, 0.04) 0.12 0.06 0.02 (0.00, 0.04) 0.14 0.04
Supine HR, beats/min −0.02 (-0.03, -0.01) 0.21 0.01 −0.02 (-0.03, -0.004) 0.21 0.01
(B) Without Supine HR
Ln-SDNNc Ln-rMSSDd
Age, year 0.02 (-0.01, 0.04) 0.07 0.14 0.01 (-0.01, 0.04 0.05 0.199
TLC, % predicted 0.01 (0.00, 0.02) 0.13 0.047 0.01 (0.00, 0.02) 0.13 0.047
HRR, beat −0.04 (-0.07, -0.003) 0.14 0.03 −0.04 (-0.07, -0.01) 0.16 0.02
Bolded variables indicate statistically signiﬁcant association at p < 0.05.
6MWT= six-minute walk test; CI= conﬁdence interval; HR=heart rate; HRR=heart rate recovery; HRV=heart rate variability; HRV=heart rate variability;
Ln= natural logarithm; MVA=multivariable linear regression analysis; O2 = oxygen; SDNN= standard deviation of normal-to-normal R-R intervals; rMSSD= root
mean square of successive diﬀerences; TLC= total lung capacity; UVA=univariable linear regression analysis.
* Step-wise backwards selection using variables with p < 0.20 from UVA (E-Table 2): age, TLC% predicted, Pre-6MWT HR, HR change, O2 saturation change, and HRR,
with and without supine HR as covariate.
a Overall model R2= 0.42, P < 0.01; no signiﬁcant interaction between age and supine HR (p=0.96), supine HR and pre-6MWT HR (p=0.68), or supine HR and HR
change (p= 0.95).
b Overall model R2= 0.42, P < 0.01; no signiﬁcant interaction between HR change and supine HR (p=0.98).
c Overall model R2= 0.31, P= 0.01; no signiﬁcant interaction between TLC% predicted and HRR (p= 0.46).
d Overall model R2= 0.30, P= 0.01; no signiﬁcant interaction between TLC% predicted and HRR (p= 0.41).
D. Ha, et al. Respiratory Physiology & Neurobiology 269 (2019) 103264
4
normal compared to impaired SDNN and rMSSD, respectively were
-14.4 vs. -9.7 beats (p= 0.04) and -15.6 vs. -9.8 beats (p= 0.04)
(Fig. 3).
4. Discussion
In lung cancer survivors eligible for long-term cure, we assessed
HRV and HRR and found impairments in 59% and 65% of patients,
respectively and identiﬁed their predictors. In addition, HRV and HRR
were inter-dependently associated, supporting their utility in assessing
physical ﬁtness and/or autonomic function in the lung cancer popula-
tion. To the best of our knowledge, our study is the ﬁrst to identify
predictors of HRV and HRR in lung cancer survivors eligible for long-
term cure and characterize their inter-relationship. Similar to a pre-
vious study (Danieli et al., 2014), we report a moderate correlation
(correlation coeﬃcient 0.3-0.7) between SDNN/rMSSD and HRR.
Lung cancer survivors face many health issues that may aﬀect their
physical ﬁtness and/or autonomic function, including due to aging
(Kingwell et al., 1994), tobacco exposure (Niedermaier et al., 1993),
comorbidities including COPD (Heindl et al., 2001), heart failure
(Barretto et al., 2009), and diabetes (Karjalainen et al., 2014), and
chemotherapy treatment (Barutcu et al., 2004). In our multivariable
models, HRR explains approximately 15% of the variances in HRV,
suggesting caution against exchanging HRR for HRV. Notably, HRR can
Fig. 2. A Signiﬁcant Independent Predictors of HRV (Ln-rMSSD).
R2 values from univariable linear regression analyses; bands indicate 95% conﬁdence intervals.
HR=heart rate; HRR=heart rate recovery; HRV=heart rate variability; Ln=natural logarithm; rMSSD=root mean square of successive diﬀerences; TLC= total lung
capacity.
Fig. 2 B: Signiﬁcant Independent Predictors of HRR.
R2 values from univariable linear regression analyses; bands indicate 95% conﬁdence intervals.
6MWD= six-minute walk distance; 6MWT= six-minute walk test; HR=heart rate; HRR=heart rate recovery.
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vary depending on cardiopulmonary ﬁtness, exertional levels achieved,
and changes in HR associated with exercise testing (Pierpont and Voth,
2004), including in cancer survivors (Niederer et al., 2015). Variations
in HRR may also be related to chronotropic incompetence (Lauer et al.,
1999) which may be present in some participants included. In addition,
HRV from 10-s ECGs have increased agreement with the gold-standard
240-300-s tracings when repeated measurements are obtained (up to 3
times) (Munoz et al., 2015); we obtained HRV from single 10-s ECGs
which may additionally explain some of the variances between HRR
and HRV.
Similar to previous studies, we found HRR to be associated with age,
resting and peak HR, exercise capacity, but not with beta-blocker or
renin-angiotensin system inhibitor use (Cole et al., 1999; Karjalainen
et al., 2014). Like a previously study involving 154 COPD patients (van
Gestel et al., 2012), we found no association between HRV and func-
tional capacity; this is in contrast to another study (Karjalainen et al.,
2014) which reported a signiﬁcant independent association between
HRV as reﬂected by SDNN and rMSSD and exercise capacity in 1060
patients with coronary artery disease (CAD) with and without type 2
diabetes (DM). Diﬀerences in comorbidities (all/predominantly COPD
vs. CAD with/without DM) and sample size may explain these con-
trasting ﬁndings. We found a positive association in TLC and HRV, si-
milar to a previous report involving 30 patients with stable COPD
(Corbo et al., 2013). This ﬁnding may have important implications in
future studies aimed at assessing HRV in the lung cancer population in
which COPD is highly prevalent (Islam et al., 2015) and could reﬂect
alterations in vagal and pulmonary stretch receptor activities associated
with chronic hyperinﬂation (Undem and Kollarik, 2005). As well, we
found HR to be signiﬁcantly associated with HRV, potentially due to
physiological autonomic nervous system activity and/or the mathe-
matical nonlinear relationship between HR and ReR intervals (Sacha,
2014). Interestingly, a recent review suggests that the removal of the
HR impact on HRV may make HRV more predictive of non-cardiac
death, while the enhancement of HR on HRV may increase predictive
power for cardiac death (Sacha, 2014). Unlike existing literature
(Umetani et al., 1998; Tsuji et al., 1996), age was not associated with
HRV in multivariable analyses, possibly due to the inclusion of age in
TLC % predicted which adjusts for age in our models or a small sample
size.
Our study also suggests that on average, those with normal HRV
have an average HRR of 14- to 16-beat decreases which are signiﬁcantly
higher than those with impaired HRV. Previous studies in the cardio-
vascular and chronic lung disease populations have suggested cutoﬀ
ranges of 12- to 18-beat decreases in HRR following exercise testing to
predict outcomes (Ha et al., 2015). Based on our data, a HRR cutoﬀ of
-14 to -16 beats or less may indicate attenuated parasympathetic ner-
vous system function in lung cancer survivors eligible for long-term
cure, similar to previous studies involving HRR following the 6MWT to
predict acute exacerbations in COPD (Rodriguez et al., 2017) and
clinical worsening in pulmonary arterial hypertension (Minai et al.,
2012) patients. However, our goal was not to draw ﬁrm conclusions
about autonomic physiology but rather identify useful biomarkers for
further study and possibly for easy clinical assessment.
Traditionally, evaluation of exercise performance focuses on muscle
and cardiovascular function. The nervous system is often under-re-
cognized despite having important physiological bases: somatic
Table 4
MVA – Independent Predictors of HRR.
All Participants (N=69)a Excluding Atrial Arrhythmia (N=52)b
Variable β (95% CI) Partial R2 P-value β (95% CI) Partial R2 P-value
Age, year 0.17 (0.04, 0.30) 0.10 0.01 0.26 (0.13, 0.39) 0.25 <0.001
Hyperlipidemia (N/Y) −2.30 (-4.98, 0.39) 0.05 0.09 N/A* N/A* N/A*
HFrEF (N/Y) N/A N/A N/A −3.32 (-5.78, -0.86) 0.14 0.01
Pre-6MWT HR, beats/min −0.15 (-0.31, 0.007) 0.06 0.06 −0.08 (-0.25, 0.08) 0.02 0.32
HR change, beats/min −1.32 (-1.82, -0.81) 0.31 <0.001 −1.31 (-1.92, -0.69) 0.29 <0.001
Pre-6MWT HR×HR change 0.01 (0.007, 0.02) 0.19 <0.001 0.01 (0.004, 0.02) 0.16 0.01
Bolded variables indicate statistically signiﬁcant association at p < 0.05.
6MWD= six-minute walk distance; 6MWT= six-minute walk test; ACE-I= angiotensin converting enzyme inhibitor; ARB=angiotensin II receptor blocker;
BMI=body-mass index; CI= conﬁdence interval; DBP=diastolic blood pressure; DLCO = diﬀusion capacity of the lung for carbon monoxide; HFrEF=heart failure
with reduced ejection fraction; HR=heart rate; HRR=heart rate recovery; MVA=multivariable linear regression analysis; SBP= systolic blood pressure;
UVA=univariable linear regression analysis.
a Step-wise backwards selection using variables with p < 0.20 from UVA (E-Table 3): age, BMI, hyperlipidemia, atrial arrhythmia, DLCO % predicted, pre-6MWT HR, HR
change, SBP change, 6MWD; overall model R2= 0.66, p < 0.001; no signiﬁcant interaction between age and pre-6MWT HR (p= 0.22).
b Step-wise backwards selection using variables with p < 0.20 from UVA (E-Table 3): age, white race, sex, hyperlipidemia, HFrEF, ACE-I/ARB, pre-6MWT HR, pre-6MWT
DBP, HR change, SBP change, 6MWD; overall model R2= 0.71, p < 0.001; no signiﬁcant interaction between age and pre-6MWT HR (p=0.57), or HFrEF and pre-6MWT
HR (p= 0.49).
* Variable not included in ﬁnal model (excluded in step-wise backwards selection).
Fig. 3. Diﬀerences in HRR between
Impaired and Normal HRV (A: SDNN
and B: rMSSD).
P-values from independent sample t-tests
(equal variances not assumed as de-
termined by Levene’s test for equality of
variances); horizontal lines inside the
boxes represent the median values, ends of
boxes upper and lower quartiles, and
whiskers highest and lowest observations.
HRR=heart rate recovery;
HRV=heart rate variability;
SDNN= standard deviation of normal-
to-normal R-R intervals; rMSSD= root
mean square of successive diﬀerences.
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innervations facilitate voluntary motor control, the sympathetic ner-
vous system activates a “ﬁght-or-ﬂight” response at the beginning of
exercise, and parasympathetic system a “rest-and-digest” state in re-
covery. While HRR is associated with exercise capacity partly due to the
nature of the test (exercise is needed to assess recovery), a blunted HRR
may be more closely related to physical inactivity than comorbidities
according to one study (Karjalainen et al., 2014). Therefore, HRR may
reﬂect another domain of ﬁtness that is useful in the lung cancer po-
pulation. We previously reported associations between impaired HRR
and perioperative cardiopulmonary complications following lung
cancer resection surgery (Ha et al., 2015b), and survival in patients
undergoing stereotactic body radiotherapy for early-stage lung cancer
(Ha et al., 2015a). Others have also reported an association between
HRV and survival in cancer patients in a systematic review and meta-
analysis (Zhou et al., 2016). Together, these data provide supporting
evidence on the importance of these measures in the lung cancer po-
pulation.
Exercise has been shown to be eﬀective in improving QoL and
function in cancer survivors (Buﬀart et al., 2017). However, the evi-
dence of eﬀectiveness is not as consistent in lung cancer survivors
compared to other cancers (Bade et al., 2015), possibly due to unique
characteristics in lung cancer as discussed above. Physiological eva-
luation in lung cancer survivors may help identify patients at risk for
clinical worsening who may beneﬁt from additional health services
(e.g. rehabilitation and/or exercise programs) to improve health. Phy-
siological measures that are readily available may help identify at-risk
individuals, monitor their health changes, and evaluate the eﬀective-
ness of health interventions. HRR and HRV from 10-s ECGs are rela-
tively easy to obtain, have been demonstrated to be responsive to ex-
ercise training (Bellenger et al., 2016; Snoek et al., 2013), and therefore
may have such utility in lung cancer patients. Unlike HRR, HRV can be
obtained at rest and therefore is not subjected to variations in patient
eﬀort associated with exercise testing. In our study, a higher number of
early stage lung cancer survivors who underwent surgical resection had
HRV measurements, suggesting that HRV can be readily assessed from
routine pre-operative ECGs.
Our study has limitations. First, our small sample size may not be
adequately powered to detect signiﬁcant associations between lung
cancer-speciﬁc characteristics including stage and treatment modality
and these heart rate measures; however a previous analysis of 133
NSCLC patients reported that HRV on 10-s ECGs were lower in stage I-II
compared to stage III-IV NSCLC [mean (SD) rMSSD=15.6 (11.5) vs
20.3 (23.5) ms, respectively, p= 0.01] (De Couck and Gidron, 2013),
suggesting lung cancer-speciﬁc eﬀects. Second, we did include other
factors including ratings of perceived exertion (RPE) during the 6MWT
which may limit our interpretation of the predictors of HRR; however
the change in HR during exercise testing has been shown to correlate
very well (correlation coeﬃcient 0.74) with RPE (Scherr et al., 2013)
and therefore could be an indirect measure. Third, we did not measure
HRV using the gold-standard 240-300-s or longer (e.g. 10-20-min)
tracings; however, HRV measures from single 10-s ECGs have been
shown to correlate and agree very well with the gold-standard as ana-
lyzed by correlation coeﬃcients (r=0.758 – 0.764 and 0.853 – 0.862
for SDNN and rMSSD, respectively), Bland-Altman 95% limits of
agreements (bias= 0.398 – 0.416 and 0.079 – 0.096), and Cohen’s d
statistics (d= 0.855 – 0.894 and 0.150 – 0.171) (Munoz et al., 2015). In
addition, a recent review of HRV in cancer patients identiﬁed ﬁve
studies involving 1396 patients showed that HRV measures from 10-s
ECGs are predictive of survival, associated with tumor burden/cancer
stage, and low compared to healthy controls (Kloter et al., 2018). As
well, HRV from 10-s ECGs has been shown to be predictive of cardiac
death in a population of 5272 patients aged ≥ 55 years (de Bruyne
et al., 1999) and overall survival in 1175 patients aged≥ 45 years and
free of cardiovascular disease and risk factors included in the Multi-
Ethnic Study of Atherosclerosis (O’Neal et al., 2016). Equally im-
portant, reference norms and ranges for HRV measures from 10-s ECGs
have been proposed for cancer (De Couck and Gidron, 2013) and non-
cancer (O’Neal et al., 2016) patient populations. Therefore, HRV mea-
sures from 10-s ECG have concurrent, predictive, and discriminant
validity. While there is supporting evidence for HRV metrics from ECG
including 10-s tracings, we also recognize that temporal analyses for
HRV are susceptible to non-stationarities and may be better addressed
using techniques such as phase-rectiﬁed signal averaging (Campana
et al., 2010), which was not performed in our study. Fourth, we did not
assess other measures of autonomic function (e.g. baroreﬂex sensitivity,
muscle sympathetic nerve activity, plasma catecholamines) or cardi-
orespiratory ﬁtness [e.g. maximal oxygen consumption (VO2max)] and
cannot give insights into its pathophysiological mechanisms in lung
cancer survivors due to the descriptive nature of our study and the
absence of related clinical outcomes. Fifth, the single-institutional
nature involving a predominantly white male veteran population and/
or referral and survivor bias may limit the generalizability of our
ﬁndings.
The strengths of our study include a thorough list of comorbidities
and potential confounders relevant in the lung cancer population in-
cluding tobacco exposure history and lung function. Also, all baseline
characteristics were collected and veriﬁed by a board-certiﬁed physi-
cian to maximize accuracy, and all physiological assessments including
the HRV, 6MWT, and HRR measurements were performed by one ob-
server, limiting inter-operator variability. In addition, we performed
thorough analyses to identify predictors of HRV and HRR that included
adjustments for resting supine and upright HR measures, facilitating
interpretation of our ﬁndings. Last, we detected a moderate correla-
tion/association between HRV and HRR, further providing evidence for
their inter-relationship.
In conclusion, we assessed and identiﬁed predictors of HRV and
HRR in lung cancer survivors eligible for long-term cure. HRV and HRR
are interrelated measures, are relatively easy to obtain, and may have
diagnostic, predictive, and prognostic value in the lung cancer popu-
lation. Studies aimed at improving lung cancer survivorship including
through rehabilitation and exercise training may consider these mea-
sures for stratiﬁcation and/or as physiological outcomes.
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